MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jtd-2026-1-0489

Медицинская библиотека · Journal of thoracic disease · 2026

Small-cell transformation of advanced non-small-cell lung cancer harboring driver mutations following tyrosine kinase inhibitor therapy: a multicenter real-world study.

Lu Yuhai, Kang Xiaoliang, Xu Qiang, Zhou Yu, Li Changbo, Hu Hongxia, Chen Mao

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Tyrosine kinase inhibitors (TKIs) are a mainstay of therapy for advanced non-small-cell lung cancer (NSCLC) harboring actionable driver mutations. However, histologic transformation from NSCLC to small-cell lung cancer (SCLC) represents a particularly challenging mechanism of treatment resistance. This study aimed to characterize the incidence, timing, and clinical outcomes of SCLC transformation in this population in routine clinical practice.

METHODS

This multicenter real-world cohort study included consecutive patients with stage III-IV NSCLC treated at three hospitals in Sichuan Province, China, between January 2018 and December 2021. Eligible patients had pathologically confirmed NSCLC, driver mutations, baseline whole-body imaging, complete clinical data, and received TKIs. Re-biopsy was performed to evaluate histologic changes. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared with the log-rank test.

RESULTS

Among 387 enrolled patients, driver mutations included EGFR (73.4%), ALK (12.6%), ROS1 (8.3%), and HER2 (5.7%). First-line treatment was TKI monotherapy in 75.2% and TKI-based combinations in 24.8%. Of the 251 patients (64.9%) who underwent re-biopsy, SCLC transformation was identified in 36 patients (14.3%). Transformation occurred predominantly after first-line TKI therapy (27/36), with additional cases after second-line therapy (9/36). OS and PFS were significantly shorter in patients with transformed SCLC than in non-transformed patients.

CONCLUSIONS

In this multicenter real-world cohort study of driver-mutated advanced NSCLC treated with TKIs, SCLC transformation was not rare among re-biopsied patients and occurred mainly after first-line therapy. These findings support a low threshold for repeat tissue sampling at disease progression to detect SCLC transformation and guide timely transition to SCLC-directed treatment.

Для цитирования: Lu Yuhai, Kang Xiaoliang, Xu Qiang, Zhou Yu, Li Changbo, Hu Hongxia, Chen Mao. Small-cell transformation of advanced non-small-cell lung cancer harboring driver mutations following tyrosine kinase inhibitor therapy: a multicenter real-world study.. Journal of thoracic disease. 2026. DOI: 10.21037/jtd-2026-1-0489.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.